Two Treatment Modalities for Myogenous Temporomandibular Disorders
Temporomandibular disorder (TMD) is a common condition with multifactorial etiology, including trauma, emotional stress, parafunctional habits, and occlusal discrepancies. TMD may be classified as myogenous, involving the masticatory and cervical muscles, or arthrogenous, affecting the temporomandibular joint structure
| Condition(s) | TMD |
|---|---|
| Status | Recruiting |
| Phase | NA |
| Study type | Interventional |
| Summary | Temporomandibular disorder (TMD) is a common condition with multifactorial etiology, including trauma, emotional stress, parafunctional habits, and occlusal discrepancies. TMD may be classified as myogenous, involving the masticatory and cervical muscles, or arthrogenous, affecting the temporomandibular joint structures. Management approaches range from noninvasive to invasive methods. The intraoral stabilization appliance (SA) is a widely used noninvasive treatment, while the ear stent (ES) has recently been introduced for managing myogenous TMD. Aim: This randomized clinical trial aims to compare the effectiveness of SA and ES in the management of myogenous TMD. |
| Who can participate | Inclusion Criteria: * Participants presenting with pain score grading at least 4 out of 10 on NRS. * Participants with fully dentate type I occlusion. * Patients experiencing no neurological disorders. Exclusion Criteria: * Patients with arthrogenous TMJ will be excluded by Magnetic Resonance Imagining (MRI) * Patients who have clicking or crepitation. * Previous history of TMD treatment. * History of recent trauma. * The presence of systemic diseases (i.e., rheumatoid arthritis, osteoarthritis myologic or arthrological disease). * Vascular disease (migraine and hypertension). * Participants with uncontrolled systemic disease (diabetes), hematologic or neurologic disorders or inflammatory diseases. * Patients who: Underwent trigger point myofascial injection, intramuscular stimulation, or |
| Ages | 18 Years to 45 Years |
| Sex | All |
| Lead sponsor | Alexandria University |
| Locations | Alexandria, Egypt |
| Start date | 2025-01-01 |
| NCT ID | NCT07351812 |
| Official listing | https://clinicaltrials.gov/study/NCT07351812 |